Precigen Announces Clearance of IND to Initiate Phase I/Ib Study for PRGN-3007 UltraCAR-T^® in Advanced ROR1+ Hematological and Solid Tumors

Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.